Chicago Equity Partners LLC bought a new stake in shares of Bruker Co. (NASDAQ:BRKR) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 15,465 shares of the medical research company’s stock, valued at approximately $531,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Ameriprise Financial Inc. lifted its stake in shares of Bruker by 296.7% in the 2nd quarter. Ameriprise Financial Inc. now owns 98,231 shares of the medical research company’s stock worth $2,833,000 after purchasing an additional 73,469 shares during the period. BlackRock Inc. lifted its stake in shares of Bruker by 3.0% in the 2nd quarter. BlackRock Inc. now owns 4,747,514 shares of the medical research company’s stock worth $136,918,000 after purchasing an additional 139,792 shares during the period. UBS Asset Management Americas Inc. lifted its stake in shares of Bruker by 25.6% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 91,748 shares of the medical research company’s stock worth $2,646,000 after purchasing an additional 18,690 shares during the period. Parametric Portfolio Associates LLC lifted its stake in shares of Bruker by 8.0% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 183,958 shares of the medical research company’s stock worth $5,305,000 after purchasing an additional 13,560 shares during the period. Finally, Stifel Financial Corp bought a new position in shares of Bruker in the 2nd quarter worth approximately $575,000. Institutional investors and hedge funds own 65.63% of the company’s stock.

Several equities analysts have recently weighed in on BRKR shares. Zacks Investment Research cut shares of Bruker from a “buy” rating to a “hold” rating in a research note on Friday, November 10th. Citigroup increased their price objective on shares of Bruker from $29.00 to $34.00 and gave the stock a “neutral” rating in a research note on Friday, November 3rd. Cowen reiterated a “hold” rating and issued a $29.00 price objective on shares of Bruker in a research note on Friday, November 3rd. Bank of America upgraded shares of Bruker from an “underperform” rating to a “neutral” rating and set a $34.00 price objective on the stock in a research note on Friday, November 3rd. Finally, JPMorgan Chase & Co. upgraded shares of Bruker from an “underweight” rating to a “neutral” rating and set a $28.00 price objective on the stock in a research note on Friday, November 3rd. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $32.29.

Shares of Bruker Co. (NASDAQ:BRKR) opened at $30.59 on Friday. Bruker Co. has a one year low of $21.83 and a one year high of $36.53. The company has a market cap of $4,918.89, a P/E ratio of 62.43, a price-to-earnings-growth ratio of 2.34 and a beta of 1.05. The company has a current ratio of 2.60, a quick ratio of 1.60 and a debt-to-equity ratio of 0.65.

Bruker (NASDAQ:BRKR) last released its earnings results on Thursday, February 8th. The medical research company reported $0.51 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.02. Bruker had a net margin of 4.45% and a return on equity of 26.58%. The company had revenue of $530.50 million for the quarter, compared to analysts’ expectations of $506.74 million. During the same quarter last year, the business earned $0.46 EPS. The firm’s revenue was up 12.8% compared to the same quarter last year. equities analysts forecast that Bruker Co. will post 1.34 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2018/02/11/chicago-equity-partners-llc-buys-shares-of-15465-bruker-co-brkr.html.

About Bruker

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Co. (NASDAQ:BRKR).

Institutional Ownership by Quarter for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.